Molecularly Targeted Therapies for Malignant Gliomas

被引：24

作者：

Argyriou, Andreas A. ^{[1
]}

Kalofonos, Haralabos P. ^{[1
]}

机构：

[1] Univ Patras, Sch Med, Univ Hosp, Dept Med,Div Clin Oncol, Rion 26504, Greece

来源：

MOLECULAR MEDICINE | 2009年 / 15卷 / 3-4期

关键词：

GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; PROTEIN-KINASE-C; GLIOBLASTOMA-MULTIFORME; MONOCLONAL-ANTIBODY; IMATINIB MESYLATE; GENETIC PATHWAYS; CANCER; RADIOIMMUNOTHERAPY; RADIOTHERAPY;

D O I：

10.2119/molmed.2008.00123

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

This review critically evaluates current knowledge of molecularly targeted therapies of malignant gliomas. Various molecularly targeted single-agent therapies, including targeted therapies of growth and survival, have been evaluated in clinical trials but have failed to demonstrate a significant survival benefit compared with standard treatment regimens. The efficacy of multi-targeted kinase inhibitors or combinations of single-targeted kinase inhibitors is a promising strategy, but requires additional clinical evaluation before definitive conclusions can be made. Important areas for further research include the assessment of serum or tissue biomarkers, the elucidation of prognostic molecular markers, and the determination of whether the mechanism of action of a drug is appropriate to the genetic alterations observed within individual tumors. (C) 2009 The Feinstein Institute for Medical Research, www.feinsteininstitute.org Online address: http://www.molmed.org doi: 10.2119/moImed.2008.00123

引用

页码：115 / 122

页数：8

共 67 条

[1]

Blocking oncogenic Ras signaling for cancer therapy [J].

Adjei, AA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (14) :1062-1074

[2]

Akabani G, 2005, J NUCL MED, V46, P1042

[3]

Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model [J].

Anderson, SA ;

Glod, J ;

Arbab, AS ;

Noel, M ;

Ashari, P ;

Fine, HA ;

Frank, JA .

BLOOD, 2005, 105 (01) :420-425

[4]

ARGYRIOU AA, 2008, CRIT REV ONCOL HEMAT

[5]

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].

Batchelor, Tracy T. ;

Sorensen, A. Gregory ;

di Tomaso, Emmanuelle ;

Zhang, Wei-Ting ;

Duda, Dan G. ;

Cohen, Kenneth S. ;

Kozak, Kevin R. ;

Cahill, Daniel P. ;

Chen, Poe-Jou ;

Zhu, Mingwang ;

Ancukiewicz, Marek ;

Mrugala, Maciej M. ;

Plotkin, Scott ;

Drappatz, Jan ;

Louis, David N. ;

Ivy, Percy ;

Scadden, David T. ;

Benner, Thomas ;

Loeffler, Jay S. ;

Wen, Patrick Y. ;

Jain, Rakesh K. .

CANCER CELL, 2007, 11 (01) :83-95

[6]

CBTRUS, 2006, STAT REP PRIM BRAIN

[7]

Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: Correlation with histopathology [J].

Cha, S ;

Johnson, G ;

Wadghiri, YZ ;

Jin, O ;

Babb, J ;

Zagzag, D ;

Turnbull, DH .

MAGNETIC RESONANCE IN MEDICINE, 2003, 49 (05) :848-855

[8]

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme [J].

Chang, SM ;

Wen, P ;

Cloughesy, T ;

Greenberg, H ;

Schiff, D ;

Conrad, C ;

Fink, K ;

Robins, HI ;

De Angelis, L ;

Raizer, J ;

Hess, K ;

Aldape, K ;

Lamborn, KR ;

Kuhn, J ;

Dancey, J ;

Prados, MD .

INVESTIGATIONAL NEW DRUGS, 2005, 23 (04) :357-361

[9]

Modulation of radiation response by histone deacetylase inhibition [J].

Chinnaiyan, P ;

Vallabhaneni, G ;

Armstrong, E ;

Huang, SM ;

Harari, PM .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (01) :223-229

[10]

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium study [J].

Cloughesy, Timothy F. ;

Wen, Patrick Y. ;

Robins, H. Ian ;

Chang, Susan M. ;

Groves, Morris D. ;

Fink, Karen L. ;

Junck, Larry ;

Schiff, David ;

Abrey, Lauren ;

Gilbert, Mark R. ;

Lieberman, Frank ;

Kuhn, John ;

DeAngelis, Lisa M. ;

Mehta, Minesh ;

Raizer, Jeff J. ;

Yung, W. K. Alfred ;

Aldape, Ken ;

Wright, John ;

Lamborn, Kathleen R. ;

Prados, Michael D. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (22) :3651-3656

← 1 2 3 4 5 6 7 →